Shenzhen Neptunus Bioengineering Co

Shenzhen Neptunus Bioengineering Co Capital Intensity

The Capital Intensity Ratio of Shenzhen Neptunus Bioengineering Co (000078.SZ) as of Oct 29, 2026 is 98.75 %. In the previous year, Capital Intensity Ratio was 94.99 % — a change of 3.96% (higher).

Capital Intensity

98.75 %

YoY

3.96%

Last updated:

Capital Intensity Ratio of Shenzhen Neptunus Bioengineering Co is 2025 98.75 % . Capital Intensity Ratio of Shenzhen Neptunus Bioengineering Co was 2024 94.99 % . It decreases by 3.96% higher compared to the previous year.

The Shenzhen Neptunus Bioengineering Co Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
107.15 CNY
Jan 1, 2019
99.22 CNY
Jan 1, 2020
99.25 CNY
Jan 1, 2021
91.60 CNY
Jan 1, 2022
95.82 CNY
Jan 1, 2023
88.70 CNY
Jan 1, 2024
94.99 CNY
Jan 1, 2025
98.75 CNY
The Shenzhen Neptunus Bioengineering Co Capital Intensity history
YEARCapital IntensityYoY
98.75 %+3.96%
94.99 %+7.09%
88.70 %-7.42%
95.82 %+4.61%
91.60 %-7.71%
99.25 %+0.03%
99.22 %-7.41%
107.15 %-13.42%
123.76 %+1.06%
122.46 %+6.68%
114.79 %+16.83%
98.26 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shenzhen Neptunus Bioengineering Co Stock analysis

What does Shenzhen Neptunus Bioengineering Co do? Shenzhen Neptunus Bioengineering Co., Ltd. generates revenue through its pharmaceutical products and healthcare offerings. The company produces anti-tumor products, cardiovascular drugs, marine drugs, respiratory drugs, anti-infective products, and other pharmaceuticals. It also sells healthcare products, health food, and medical instruments. The primary market for these products is the domestic market, with East China being the main regional focus. The company serves healthcare providers, hospitals, and consumers within China's pharmaceutical sector. Neptunus targets the Chinese domestic market, emphasizing East China as its core region. Its product portfolio spans multiple therapeutic areas including oncology, cardiology, respiratory care, and infection control. The company's distribution network focuses on reaching hospitals and healthcare facilities across China, particularly in the East China region. The firm's health food and medical instrument lines complement its pharmaceutical business, creating diversified revenue streams within the healthcare industry. The business model relies on selling established pharmaceutical products alongside healthcare and medical solutions. Anti-tumor products and cardiovascular drugs form key segments of its revenue, supported by marine drugs and respiratory medications. East China's dominance in sales reflects the company's strategic market focus. The company's full-time employee count of 9,874 supports its manufacturing and distribution operations across China's domestic market. Shenzhen Neptunus Bioengineering Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shenzhen Neptunus Bioengineering Co stock

Capital Intensity Ratio of Shenzhen Neptunus Bioengineering Co is 98.75 % in 2025.

Capital Intensity Ratio of Shenzhen Neptunus Bioengineering Co changed from 94.99 % to 98.75 %, representing a 3.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Shenzhen Neptunus Bioengineering Co since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Shenzhen Neptunus Bioengineering Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Shenzhen Neptunus Bioengineering Co

All Key Metrics — Shenzhen Neptunus Bioengineering Co